Hereditary Angioedema: On-demand Treatment and Long-term Prophylaxis – A Global Reality

Clicks: 6
ID: 322534
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #25 of 31 articles by views in Clinical & Experimental Immunology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Hereditary Angioedema (HAE) is a rare disorder of recurrent swellings of the subcutaneous and/or mucosal tissues due to defects in the contact system regulation of bradykinin production. The swellings can be disfiguring, cause debilitating abdominal pain, or be fatal with laryngeal obstruction. Over the last decade there has been immense successes in management of HAE owing to development of drugs targeting the contact system. This review focuses on management of HAE due to C1-INH deficiency/dysfunction including a global perspective which is under-represented in the literature. HAE with normal C1-INH is outside the scope of this article. The review provides summaries of clinical trials that has led to licensing of new HAE medications and discusses access to these modern drugs from a global perspective.
Reference Key
openalex_W7171083464 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cassim Akhoon, Sorena Kiani‐Alikhan
Journal Clinical & Experimental Immunology
Year 2026
DOI
10.1093/cei/uxag043
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.